These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 15059147)

  • 21. Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?
    Cooper N; Evangelista ML; Amadori S; Stasi R
    Curr Opin Hematol; 2007 Nov; 14(6):642-6. PubMed ID: 17898569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting response to splenectomy in children with immune thrombocytopenic purpura.
    Wood JH; Partrick DA; Hays T; Ziegler MM
    J Pediatr Surg; 2010 Jan; 45(1):140-4; discussion 144. PubMed ID: 20105594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rituximab in the treatment of relapsing idiopathic thrombocytopenic purpura.
    Riksen NP; Keuning JJ; Vreugdenhil G
    Neth J Med; 2003 Jul; 61(7):262-5. PubMed ID: 14567524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment.
    Wang J; Wiley JM; Luddy R; Greenberg J; Feuerstein MA; Bussel JB
    J Pediatr; 2005 Feb; 146(2):217-21. PubMed ID: 15689912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of splenectomy in adult chronic immune thrombocytopenia.
    Zoghlami-Rintelen C; Weltermann A; Bittermann C; Kyrle PA; Pabinger I; Lechner K; Wenzl E
    Ann Hematol; 2003 May; 82(5):290-4. PubMed ID: 12739064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Refractory autoimmune thrombocytopenic purpura: responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab).
    Narang M; Penner JA; Williams D
    Am J Hematol; 2003 Dec; 74(4):263-7. PubMed ID: 14635207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of dapsone as a second-line treatment in non-splenectomized adults with immune thrombocytopenic purpura.
    Vancine-Califani SM; De Paula EV; Ozelo MC; Orsi FL; Fabri DR; Annichino-Bizzacchi JM
    Platelets; 2008 Nov; 19(7):489-95. PubMed ID: 18979360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP).
    Alasfoor K; Alrasheed M; Alsayegh F; Mousa SA
    Ann Hematol; 2009 Mar; 88(3):239-43. PubMed ID: 18704420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Idiopathic thrombocytopenic purpura associated with mantle cell lymphoma showing an increase in the platelet count receiving anti-CD20 antibody rituximab].
    Kawachi Y; Ide M; Uchida T; Setsu K
    Rinsho Ketsueki; 2003 Jan; 44(1):31-3. PubMed ID: 12649836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Critical issues of current and future developments in the treatment of immune thrombocytopenic purpura.
    Koene HR
    Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):703-5. PubMed ID: 16933273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical efficacy of lower dose rituximab for chronic refractory immune thrombocytopenic purpura].
    Li Y; Wang XM; Mao M; Zhang XY; Fu L; Ai HM; Zhang LX
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):204-6. PubMed ID: 22781608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical remission following monoclonal anti-CD20 therapy in two children with chronic refractory idiopathic thrombocytopenic purpura.
    Moschovi M; Trimis G; Pergantou H; Platokouki H; Vrachnou E; Tzortzatou-Stathopoulou F
    J Paediatr Child Health; 2005 Jul; 41(7):384-6. PubMed ID: 16014149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results.
    Medeot M; Zaja F; Vianelli N; Battista M; Baccarani M; Patriarca F; Soldano F; Isola M; De Luca S; Fanin R
    Eur J Haematol; 2008 Sep; 81(3):165-9. PubMed ID: 18510702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP).
    Schwartz J; Leber MD; Gillis S; Giunta A; Eldor A; Bussel JB
    Am J Hematol; 2003 Feb; 72(2):94-8. PubMed ID: 12555211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rituximab treatment for symptomatic chronic ITP.
    Tamminga RY; Bruin MC
    Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):714-6. PubMed ID: 16933264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.
    Stasi R; Pagano A; Stipa E; Amadori S
    Blood; 2001 Aug; 98(4):952-7. PubMed ID: 11493438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia.
    Lauria F; Lenoci M; Annino L; Raspadori D; Marotta G; Bocchia M; Forconi F; Gentili S; La Manda M; Marconcini S; Tozzi M; Baldini L; Zinzani PL; Foà R
    Haematologica; 2001 Oct; 86(10):1046-50. PubMed ID: 11602410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Immune thrombocytopenic purpura: pathophysiology and treatment].
    Godeau B
    Transfus Clin Biol; 2009 May; 16(2):101-5. PubMed ID: 19409827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of a patient with chronic immune thrombocytopenic purpura with rituximab and monitoring by flow cytometric analysis.
    Thude H; Gruhn B; Werner U; Schorner U; Häfer R; Zintl F; Barz D
    Acta Haematol; 2004; 111(4):221-4. PubMed ID: 15153715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis.
    Garcia-Chavez J; Majluf-Cruz A; Montiel-Cervantes L; Esparza MG; Vela-Ojeda J;
    Ann Hematol; 2007 Dec; 86(12):871-7. PubMed ID: 17874322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.